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CC BY-NC-ND license (http://creativeBackground: Neonatal hyperbilirubinemia is common in Asia, and the importance of geneti-
cally determined conditions has been recently recognized. The aim of this study was to assess
the clinical utility of genetic testing in Chinese neonates with severe hyperbilirubinemia.
Methods: Fifty-eight term infants with bilirubin level  20 mg/dL (342 mmol/L), and 65 con-
trols were enrolled in the study. Variation status of UGT1A1, G6PD, and thalassemia genes
in our study cohort was determined by direct sequencing or genotype assays.
Results: Among these case infants, seven were confirmed with G6PD deficiency, four were het-
erozygous for a- or b-thalassemia, and forty-four were detected with at least one heterozygous
UGT1A1 functional variant, including nine homozygous for UGT1A1 variation. As well as the
predominant c.211G>A (Gly71Arg) variant, three UGT1A1 coding variants [c.1091C>T (Pro364-
Leu), c.1352C>T (pro451leu), and c.1456C>T (Tyr486Asp)] were observed in our case neo-
nates. The results of multivariate logistic regressions, adjusted for covariates, revealed odds
ratios for neonates who carried heterozygous, homozygous variation at nucleotide 211 of
UGT1A1, and G6PD deficiency of 3.47 (1.26e9.55), 12.46 (1.09e142.7) ,and 12.87 (1.32
e135.87) compared with those having the wild genotype and normal G6PD activity, respec-
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Genetic basis of severe neonate jaundice 311Conclusion: Besides G6PD-deficiency screening, UGT1A1 genetic analysis, and especially the
UGT1A1*6(c.211G>A, p.Arg71Gly) polymorphism detection, may be taken into consideration
for early diagnosis and treatment of severe hyperbilirubinemic newborns in southern China.
Copyright ª 2015, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
Severe neonatal hyperbilirubinemia [total serum bilirubin
(TSB) level  20 mg/dL or > 342 mmol/L] is frequently
manifested as a pediatric complex trait or disorder, which is
still prevalent (1%) in the newborn population today.1,2
Although most cases are benign and do not result in
serious consequences, a small number of infants will
develop hazardous levels of bilirubin that pose a direct
threat of brain damage, and which may result in neuro-
developmental abnormalities, such as hearing loss, athe-
tosis, and, rarely, intellectual deficits.3e5
East Asian ancestry encompassing population across
mainland China, Hong Kong, Japan, Macau, Korea, and
Taiwan was listed as a major risk factor for severe hyper-
bilirubinemia in the 2004 American Academy of Pediatrics
clinical practice guideline.6 It was proposed that higher
incidence of hemolytic anemia, such as ABO alloimmuniza-
tion and G6PD deficiency, may predispose this population to
be sensitive to neonatal hyperbilirubinemia, and to an overall
increased risk for a TSB of  20 mg/dL (342 mmol/L).7 How-
ever, the etiology is still listed as “idiopathic” and not suffi-
ciently explored in the majority of clinically reported cases.
Genetic diagnosis has cast a new and fascinating light on
this complex disorder. The main feature in neonatal jaun-
dice may be the imbalance between increased bilirubin
production and decreased conjugation rates. There is
increasing evidence showing that genetic variants in the
key bilirubin metabolism gene in humans, hepatic bilirubin
conjugating isoenzyme uridine diphosphoglucuronosyl
transferase 1A1 (UGT1A1), as described classically for
Crigler-Najjar type I and II syndromes and reported for
Gilbert’s syndrome,8e10 were associated with increased
incidence and severity of hyperbilirubinemia in combina-
tion with hemolytic disorder.11e15
In this study, we investigated the variation status of
UGT1A1, G6PD, and thalassemia genes in neonates with
severe hyperbilirubinemia in the Chaozhou region of
southern China, where the prevalence of G6PD deficiency
and thalassemia was 2% and w6e8%, respectively.16,17 We
presumed that UGT1A1 variation, G6PD deficiency, and
thalassemia may be more frequent in these neonates with
severe hyperbilirubinemia, and that this may contribute to
their development of severe hyperbilirubinemia.2. Methods2.1. Study participants and sample collection
This was a retrospective caseecontrol study conducted in
the pediatric center of a single hospital (Chaozhou CentralHospital, affiliated with Southern Medical College, Chaoz-
hou, Taiwan). All study neonates were enrolled from those
admitted to the study center from November 2011 to July
2014. Eligible infants were term infants with a gestational
age of > 37 weeks, a birth weight  2500 g, and no major
birth abnormalities or serious illness.
Blood samples for genotyping were obtained from the
surplus ethylenediaminetetraacetic acid anti-coagulated
whole-blood sample, which was prospectively collected
and stored 20C after completion of the clinical diagnosis.
Clinical records, including the birth date, gender, birth
weight, delivery method, gestational age, feeding method,
TSB levels, and peak bilirubin levels before phototherapy
were reviewed.
Severe neonatal hyperbilirubinemia was defined as a TSB
concentration > 20 mg/dL (342 mmol/L).2 The recorded
peak TSB was used to divide the enrolled participants into
case and control groups. The case group included jaundiced
infants with a maximum TSB > 20 mg/dL and aged 
14 days. Neonates with known clinical risk factors for
developing neonatal hyperbilirubinemia, such as a positive
Coombs’ test, cephalohematoma, sepsis, perinatal
asphyxia, or major organ abnormality, were excluded.
Control infants were term infants without major abnor-
mality or illness, who were admitted to the study center for
reasons other than jaundice during the same period, and
with a TSB not requiring phototherapy according to the
updated clinical guidelines by the China Neonatal
Association.18
The study was approved by the Institute Ethics Com-
mittee of Chaozhou Central Hospital. Since the data were
analyzed anonymously and blood samples for this study
were used after the completion of clinical diagnostic work
(blood routine test), the committee approved a waiver of
written consent.2.2. Analysis of UGT1A1 polymorphism
Samples from jaundiced babies were subjected to direct
sequencing of the UGT1A1 genes. Samples from babies in
the control group were only subjected for *6(c.211G>A,
p.Arg71Gly) and TATA-box UGT1A1 polymorphism analyses.
The promoter, all five exons, exon-intron boundaries,
and a region in the distal promoter (the phenobarbital-
response enhancer module) of UGT1A1 were tested by po-
lymerase chain reaction (PCR) amplification and direct
sequencing as previously described.19
Repeat polymorphism, (TA)n, in the promoter region was
further confirmed by capillary electrophoresis analysis. For
this analysis, promoter regions were specifically PCR
amplified with a FAM-labeled sense primer. Fluorescent
amplicons were generated on the ABI 3100 Genetic
Table 1 Demographic and clinical features of neonates in
case and control groups.
Case (n Z 58) Control (n Z 65) p
Sex NS
Male 35(60.3) 41(63.1) d
Female 23(39.7) 24(36.9) d
Gestational
age (wk)
38.9  1.4 39.6  0.1 0.004
Birth weight (kg) 3.08  0.42 3.27  0.37 0.012
Maximum TSB
levels
(mmol/L)
389.6
(343.8e547.6)
64.0
(w14.9e146.1)
<0.001
Feeding
Breast fed 30(51.7) 20(30.8) 0.018
Breast and
formula
14(24.1) 20(30.8) NS
Formula 9(15.5) 13(20.0) NS
Unknown 5(8.6) 12(18.5) NS
Birth delivery NS
Vaginal 35(60.3) 38(58.5) d
Cesarean 23(39.7) 27(41.5)
G6PD deficiency 7(12.1) 1(1.5) 0.026
Twin gestation 2(3.4) 0 d
Data are presented as n (%), mean  standard deviation, or
median (95% Confidence Interval).
NS Z no significance.
312 H. Yang et alAnalyzer (Applied BioSystems, Foster City, CA, USA), and
the size of the amplicons determined by using the software
GeneMapper 4.0 (Applied BioSystems). The sequence re-
sults further confirmed the sizes of (TA)n repeats as
determined by fluorescence labeling. Primer sequences for
(TA)n-repeat analysis were as follows: F: FAM-
ACGTGACACAGTCAAACATTAACT; R: CCAGCATGGGACACC-
ACTG.
The *6(c.211G>A, p.Arg71Gly) polymorphism in the
control group neonates was determined by our novel high-
resolution-melting (HRM) method. Primers used for this PCR
and HRM analysis were: F: CACCTGACGCCTCGTTGTAC; R:
CTCTTTCACATCCTCCCTTTG.
2.3. G6PD gene analysis
G6PD-deficient neonates, as determined by clinically
approved G6PD Enzyme Quantification Assay (Guangzhou
Micky Medical Instrument Co., Guangdong, China), were
further subjected to molecular analysis. A reverse dot blot
assay kit (Yaneng Biotechnology Limited Corp., Shenzhen,
China) was used for genotyping the mutations in G6PD-
deficient neonates. The assay was capable of detecting six
common mutations (c.95A>G, c.871G>A, c.1004C>T,
c.1024C>T, c.1376G>T, and c.1388G>A) in the Chinese
G6PD-deficient population.
2.4. Thalassemia analysis
All the jaundiced babies were subjected to thalassemia
gene analysis using the thalassemia detection kit (Hybribio
Biotechnology Limited Corp., Chaozhou, China). The pro-
cedure for this analysis was detailed in our previous work.20
2.5. Data analysis
A Hardy-Weinberg equilibrium (HWE) test for the two
common variants in the UGT1A1 locus was performed. Dif-
ferences in the categorical variables within the two groups
were compared by Chi-square test or Fisher’s exact test,
while continuous variables were analyzed using the Student
t test or ManneWhitney U nonparametric test. Multiple
logistic regression analysis was performed to evaluate the
independence of genetic variants of UGT1A1 and G6PD
genes associated with the development of severe hyper-
bilirubinemia. Association of the development of severe
hyperbilirubinemia was adjusted for covariates, including
gender, birth weight, gestational age, and feeding practice.
All analyses were conducted using SPSS version 16.0 (SPSS
Inc., Chicago, IL, USA). A p < 0.05 was considered statis-
tically significant.
3. Results
3.1. Demographic and clinical characteristics
Fifty-eight term infants with TSB  20 mg/dL and 65 con-
trols were enrolled in the study. They were all term infants
admitted to a hospital on approximately the 7th day of life
(range, 1e14 days). Clinical features of these participantsare summarized in Table 1. Of the selected eight factors
obtained from chart records, gestational age, birth weight,
feeding way, and G6PD deficiency showed statistically sig-
nificant differences between the case and control groups.
Mean birth weight was 3082  418 g in the case group, and
3270  368 g in the control group. Although we excluded
late preterm infants, the gestational age still differed be-
tween the two groups, with 38.9  1.4 weeks versus
39.6  0.1 weeks (p < 0.001) for the case and control
groups, respectively. Furthermore, case infants received
breastfeeding more often than control infants, and more
neonates in the case group were observed having G6PD
deficiency.
3.2. Determination of gene variations for case
versus control
3.2.1. G6PD deficiency
G6PD deficiency was confirmed in seven of 58 neonates in
the case group, and one in 65 neonates in the control group.
All seven severe hyperbilirubinemia neonates identified
with decreased G6PD enzyme activity were males. Four
kinds of mutations were detected, including c.95A>G
(n Z 1), c.1024 C>T (n Z 1), c.1376 G>C (n Z 3), and
c.1388 G>A (n Z 2)]. One male neonate in the control
group identified with a c.95A>G variation in G6PD exon 2
did not develop jaundice.
3.2.2. UGT1A1 variation
The frequencies of TATA-box polymorphism and the
*6(c.211G>A, p.Arg71Gly) variant in UGT1A1 showed sta-
tistically significant differences in distribution between the
Table 2 Genotype frequency of the (TA)n-repeat poly-
morphism and *6(c.211G > A, p.Arg71Gly) variant of
UGT1A1 case versus control groups.
Case Control Total pHeW pGenotype
(TA)n 0.13 0.025
TA6/TA6 50 (86.2) 45 (69.2) 95 (77.2)
TA6/TA7 8 (13.8) 20 (30.8) 28 (22.8)
TA7/TA7 0 0 0
G211A
variation
0.36 <0.001
G/G 24 (41.4) 51 (78.5) 75 (61.0)
G/A 25 (43.1) 13 (20.0) 38 (30.9)
A/A 9 (15.5) 1 (1.5) 10 (8.1)
Data are presented as n (%).
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significant deviation from HWE in either case or control
group neonates. As expected, more neonates in the case
group were observed to have the c.211 variants (p < 0.001).
No homozygote of the (TA)7 repeat was found in our study
cohort. Interestingly, more heterozygotes of the (TA)7
repeat variant were observed in the control group.
In addition to the variation in the UGT1A1 promoter
region [A(TA)6TAA/A(TA)7TAA (6/7)], four variant sites
within the coding region of this gene were identified in the
case group, including UGT1A1*6(c.211G>A, p.Arg71Gly),
*73(c.1091C>T, p.Pro364Leu), rs114982090 (c.1352C>T,
p.pro451leu), and *7(c.1456C>T, p.Tyr486Asp; Figure 1.
HRM analysis was established for rapid genotyping of the
c.211 mutations in all samples. As shown in Figure 2, het-
erozygous mutation could be easily distinguished from wild-
type samples based on differences in the melting-curve
shape. For the melting-curve shapes of homozygous muta-
tions, which were similar to those of wild-type, homozygousFigure 1 Mutations of UGT1A1 found in our case group. (A) c.
(Pro364Leu); (C) c.1352C>T heterozygote (pro451leu); and (D) c.1mutations were detected by a modified HRM-analysis
strategy as described our previous study.16,21 All 58 case
samples were correctly genotyped as compared with the
sequence results. Therefore, we believed that HRM may be
used as a rapid method for a large-scale investigation of
UGT1A1 gene polymorphism.3.2.3. Thalassemia detection
Four patients in the case group were identified with globin
gene mutations, including two with a-thalassemia and two
with b-thalassemia, giving a rate of 6.9% in our studied case
participants and identical to the figure reported in previous
studies of this region.17 The genotypes of the four thalas-
semia carriers were -a3.7/aa, aCSa/aa, b4142/b, andb654/b,
respectively.3.3. Association of UGT1A1 variation and G6PD
deficiency with severe neonatal hyperbilirubinemia
After controlling differences in birth weight, gestational
age, and feeding method, the nucleotide variant at position
211 of UGT1A1 and G6PD deficiency still showed association
with the development of severe hyperbilirubinemia. Spe-
cifically, neonates who carried heterozygous, homozygous
variation at nucleotide position 211 of UGT1A1, and G6PD
deficiency had a 3.47(1.26e9.55)-, 12.46(1.09e142.7)-, and
12.87(1.32e135.87)-fold risk of hyperbilirubinemia as
compared with those having the wild genotype and normal
G6PD activity, respectively (Table 3).
All the case neonates were treated with phototherapy.
Most were discharged without complication, except for
three infants who showed with signs of bilirubin encepha-
lopathy. The maximum recorded TSB for the three neonates
was 547.9 mmol/L, 390.8 mmol/L, and 340.8 mmol/L,
respectively.211G>A homozygote (Gly71Arg); (B) c.1091C>T heterozygote
456C>T homozygote (Tyr486Asp).
Figure 2 HRM analysis of the UGT1A1*6(c.211G>A, p.Arg71Gly) polymorphism. (A) Differences in the normalized plots. (B)
Differences in normalized and temperature-shifted plots. HRM Z high-resolution melting.
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Neonatal hyperbilirubinemia is common across Asia,
including China (34.4% of term neonates in China).22 Haz-
ardous hyperbilirubinemia remains not rare, especially in
some areas of south China.23 In the present study, we
explored G6PD, UGT1A1, and thalassemia gene variant
expression in severely jaundiced neonates from southern
China. Our results revealed that much of the observed se-
vere hyperbilirubinemia could be attributed to variations at
the UGT1A1 and G6PD loci. Additionally, we established a
HRM analysis that could be used for rapid and accurate
screening of the most frequent UGT1A1 mutation, the
c.211G>A (UGTA*6) variant.Table 3 Associations between independent risk factors and
regression analysis.
Case Contr
G6PD deficiency
No 43 (87.8) 51 (98
Yes 6 (12.2) 1 (1.
G211A variation
Wild type 22 (44.9) 39 (75
c.211 heterozygote 21 (42.9) 12 (23
c.211 homozygote 6 (12.2) 1 (1.
Data are presented as n (%), unless otherwise indicated.
*Adjusting for gender, birth weight, feeding way, gestational age.
CI Z confidence interval; OR Z odds ratio.To the best of our knowledge, the present study was the
first to evaluate the respective effects of the three inde-
pendent known genetic modifiers, selected as the strongest
reported to date, in a homogenous cohort of severe
hyperbilirubinemia neonates in mainland China. In a pre-
vious study, Huang et al24 investigated this issue in Taiwa-
nese neonates. Recently, Zhou et al25 studied the effect of
selected polymorphisms in two bilirubin metabolism genes
(Ho-1 and UGT1A1) in breast-fed neonates from mainland
China, but they only considered neonates with mild/mod-
erate jaundice. The present study extended the analysis by
including three main genetic modifiers involved in both
bilirubin production (G6PD and thalassemia) and meta-
bolism (UGT1A1), in a homogenous cohort of severe
hyperbilirubinemia neonates from southern China.severe neonate hyperbilirubinemia: multivariate logistic
ol Adjusted OR* (95% CI) p
.1) 1
9) 12.87(1.32e135.87) 0.0082
) 1
.1) 3.48 (1.26e9.55) 0.016
9) 12.46 (1.09e142.7) 0.043
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may support those in the clinical setting. Our results
emphasized the need to perform UGT1A1 and G6PD analysis
as an aid for neonatal hyperbilirubinemia management, as
well as family and prenatal genetic counseling of Chinese
descendants in this region.
Of the genes involved in bilirubin metabolism, UGT1A1
has been the most widely studied, given its essential role in
hepatic bilirubin glucuronidation. The c.211G>A
(UGT1A1*6) polymorphism was the most frequent UGT1A1
variant in the East Asian population. The association of
UGT1A1*6 and neonatal hyperbilirubinemia has been well
studied and docummented.12,24e28 Our detailed analysis
confirmed the strong association of this independent pre-
dictor with the risk for severe hyperbilirubinemia in our
study cohort.
In addition to UGT1A1*6, TATA polymorphisms in the
UGT1A1 promoter, described as the common cause of Gil-
bert’s syndrome in the Caucasian population,8,26 were not
associated with the increased risk of neonatal hyper-
bilirubinemia in our study cohort. Many previous studies
also observed that the frequency of the A(TA)7TAA allele in
the promoter region of UGT1A1 was substantially lower in
the Asian population, and most failed to find its correlation
with neonatal hyperbilirubinemia in this population.28 Some
studies even achieved the reverse results, i.e., both recent
studies in Chinese and Japanese breast-feeding neonates
observed that heterozygous (TA)7 mutation significantly
decreased, rather than increased, the risk of hyper-
bilirubinemia.25,27 The present study also observed that
more neonates in the control group were heterozygous for
the (TA)7 mutation, although the association decreased
after adjusting the covariate. The precise role of the TATA
polymorphism in hyperbilirubinemia merits further study.
The other three kinds of UGT1A1 coding variants found
in our case group neonates were *73(c.1091C>T,
p.Pro364Leu), rs114982090 (c.1352C>T, p.pro451leu), and
*7(c.1456C>T, p.Tyr486Asp), with each reportedly associ-
ated with a significant reduction in UGT1A1 enzyme activity
and a Gilbert’s syndrome phenotype in previous
studies8,12,29,30, except for c.1352C>T (pro451leu), whose
role in UGT1A1 isoenzyme activity has not yet been studied
using laboratory methods. Alternatively, using a bioinfor-
matics approach, rs114982090 (c.1352C>T, p.pro451leu)
was predicted to be a deleterious nsSNP by two algorithms,
sorting intolerant from tolerant (SIFT) and polymorphism
phenotyping (PolyPhen).31
G6PD deficiency is an important cause of severe
neonatal hyperbilirubinemia and kernicterus. Neonate
screening for G6PD deficiency has been established in many
countries with high disease prevalence as recommended by
the World Health Organization.32 Consistent with most
previous studies, our study revealed a strong association
between G6PD deficiency and significant hyper-
bilirubinemia in neonates.
Previous studies also indicated that heterozygous female
patients reported as enzymatically normal might still be at
risk.33e35 For this consideration, molecular diagnosis fa-
voring the detection of heterozygotes can be a supplement
to regular newborn screening, and useful for premarital and
prenatal diagnosis of G6PD deficiency.Thalassemia is another common heritable hemolytic
disorder in Southeast Asia.36 All a-thalassemia patients
identified in our study cohort were silent/mild thalassemia
carriers, reflecting defects consisting of one or two muta-
tions in a-globin or heterozygous for b-globin mutation,
which were not associated with hemolysis and severe
hyperbilirubinemia risk in neonates. As previously
mentioned, co-inheritance of thalassemia and Gilbert’s
syndrome was reported to elevate bilirubin levels in a-
thalassemia traits and b-thalassemia heterozygotes.14,15
Co-expression across these genes has been commonly
observed and might contribute to clinical severity. Fifty
percent of G6PD-deficient neonates co-inherited with at
least one UGT1A1 variant. All the four thalassemia neo-
nates combined with either G6PD deficiency or UGT1A1
variation. Our sample size did not allow us to fully char-
acterize the complexity of the interactions among these
potential contributors. However, the degree of genetic
heterogeneity and variant co-expression observed in this
cohort underscored the likely complex polygenic nature of
neonatal hyperbilirubinemia.
Except for the genetic risk factors, breast feeding was
the most frequently confirmed demographic risk factor
observed in association with hyperbilirubinemia. Further-
more, increasing evidence suggests that there may be an
additive effect between UGT1A1 variation and breast-
feeding in neonatal hyperbilirubinemia risk.37e39 However,
the mechanism underlying this phenomenon remains
elusive. Moreover, it should also be noted that in > 20% of
severe hyperbilirubinemia infants in this study no etiology
was found. This finding suggested that other genetic and/or
environmental factors beyond this study might also
contribute to the development of neonatal
hyperbilirubinemia.
One limitation of the study was the retrospective
sampling, which shaped the clinical distribution of the
cohort and the sample size, and may have limited our
ability to definitively identify common variants with rela-
tively small effect sizes of the expected type. Therefore,
a wide range of estimated confidence-interval values was
obtained from the regression analysis of homozygous var-
iations at nucleotide position 211 of UGT1A1, as well as
G6PD deficiency, for neonatal hyperbilirubinemia risk,
though the relative risk value for the homozygous c.211
variant and G6PD deficiency was much higher as compared
with the heterozygous variation at nucleotide position 211
of UGT1A1.
In conclusion, in addition to G6PD-deficiency screening,
UGT1A1 genetic analysis, especially detection of the
UGT1A1*6(c.211G > A, p.Arg71Gly) polymorphism, may
serve as a diagnostic aid for individuals with significant
hyperbilirubinemia. UGT1A1*6 polymorphism screening
should be taken into consideration for early diagnosis and
treatment of severe hyperbilirubinemia in Chinese
newborns.Conflicts of interest
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316 H. Yang et alAcknowledgments
We thank the Medical Research Fund of Guangdong Prov-
ince (B2013444 and A2014902) and the Science and Tech-
nology Research Fund of Guangdong Province
(2012B031800001) for their financial support.
References
1. Kaplan M, Bromiker R, Hammerman C. Severe neonatal
hyperbilirubinemia and kernicterus: are these still problems in
the third millennium? Neonatology 2011;100:354e62.
2. Bhutani VK, Johnson LH, Jeffrey Maisels M, Newman TB,
Phibbs C, Stark AR, et al. Kernicterus: epidemiological strate-
gies for its prevention through systems-based approaches. J
Perinatol 2004;24:650e62.
3. Newman TB, Escobar GJ, Gonzales VM, Armstrong MA,
Gardner MN, Folck BF. Frequency of neonatal bilirubin testing
and hyperbilirubinemia in a large health maintenance organi-
zation. Pediatrics 1999;104:1198e203.
4. Dennery PA, Seidman DS, Stevenson DK. Neonatal hyper-
bilirubinemia. N Engl J Med 2001;344:581e90.
5. Maisels MJ. Risk assessment and follow-up are the keys to
preventing severe hyperbilirubinemia. J Pediatr (Rio J) 2011;
87:275e6 [Article in English, Portuguese].
6. American Academy of Pediatrics Subcommittee on Hyper-
bilirubinemia. Management of hyperbilirubinemia in the
newborn infant 35 or more weeks of gestation. Pediatrics 2004;
114:297e316.
7. Ho NK. Neonatal jaundice in Asia. Baillieres Clin Haematol
1992;5:131e42.
8. Clarke DJ, Moghrabi N, Monaghan G, Cassidy A, Boxer M,
Hume R, et al. Genetic defects of the UDP-glucuronosyl
transferase-1 (UGT1) gene that cause familial non-haemolytic
unconjugated hyperbilirubinaemias. Clin Chim Acta 1997;
266:63e74.
9. Kadakol A, Ghosh SS, Sappal BS, Sharma G, Chowdhury JR,
Chowdhury NR. Genetic lesions of bilirubin uridine-
diphosphoglucuronate glucuronosyltransferase (UGT1A1)
causing Crigler-Najjar and Gilbert syndromes: correlation of
genotype to phenotype. Hum Mutat 2000;16:297e306.
10. Watchko JF, Daood MJ, Biniwale M. Understanding neonatal
hyperbilirubinaemia in the era of genomics. Semin Neonatol
2002;7:143e52.
11. Saki F, Hemmati F, Haghighat M. Prevalence of Gilbert syn-
drome in parents of neonates with pathologic indirect hyper-
bilirubinemia. Ann Saudi Med 2011;31:140e4.
12. Huang CS, Chang PF, Huang MJ, Chen ES, Chen WC. Glucose-6-
phosphate dehydrogenase deficiency, the UDP-glucuronosyl
transferase 1A1 gene, and neonatal hyperbilirubinemia.
Gastroenterology 2002;123:127e33.
13. Kaplan M, Renbaum P, Levy-Lahad E, Hammerman C, Lahad A,
Beutler E. Gilbert syndrome and glucose-6-phosphate dehy-
drogenase deficiency: a dose-dependent genetic interaction
crucial to neonatal hyperbilirubinemia. Proc Natl Acad Sci U S A
1997;94:12128e32.
14. Dabke PS, Colah RB, Ghosh KK, Nadkarni AH. Role of co-
inherited Gilbert syndrome on hyperbilirubinemia in Indian
beta thalassemia patients. Hematology 2014;19:388e92.
15. Galanello R, Perseu L, Melis MA, Cipollina L, Barella S, Giagu N,
et al. Hyperbilirubinaemia in heterozygous beta-thalassaemia
is related to co-inherited Gilbert’s syndrome. Br J Haematol
1997;99:433e6.
16. Yang H, Wang Q, Zheng L, Zhan XF, Lin M, Lin F, et al. Incidence
and molecular characterization of Glucose-6-PhosphateDehydrogenase deficiency among neonates for newborn
screening in Chaozhou, China. Int J Lab Hematol 2015;37:
410e9.
17. Yin A, Li B, Luo M, Xu L, Wu L, Zhang L, et al. The prevalence
and molecular spectrum of a- and b-globin gene mutations in
14,332 families of Guangdong Province, China. PLoS ONE 2014;
9:e89855.
18. Editorial Board of Chinese Journal of Pediatrics; Subspecialty
Group of Neonatology. The Society of Pediatrics, Chinese
Medical Association. Experts consensus on principles for diag-
nosis and treatment of neonatal jaundice. Zhonghua Er Ke Za
Zhi 2010;48:685e6 [Article in Chinese].
19. Aono S, Yamada Y, Keino H, Sasaoka Y, Nakagawa T, Onishi S,
et al. A new type of defect in the gene for bilirubin uridine 5’-
diphosphate-glucuronosyltransferase in a patient with Crigler-
Najjar syndrome type I. Pediatr Res 1994;35:629e32.
20. Lin M, Zhu JJ, Wang Q, Xie LX, Lu M, Wang JL, et al. Devel-
opment and evaluation of a reverse dot blot assay for the
simultaneous detection of common alpha and beta thalassemia
in Chinese. Blood Cells Mol Dis 2012;48:86e90.
21. Pan M, Lin M, Yang L, Wu J, Zhan X, Zhao Y, et al. Glucose-6-
phosphate dehydrogenase (G6PD) gene mutations detection
by improved high-resolution DNA melting assay. Mol Biol Rep
2013;40:3073e82.
22. Ding G, Zhang S, Yao D, Na Q, Wang H, Li L, et al. An epide-
miological survey on neonatal jaundice in China. Chin Med J
(Engl) 2001;114:344e7.
23. Subspecialty Group of Neonatology, Society of Pediatrics,
Chinese Medical Association, Chinese Multicenter Study Coor-
dination Group for Neonatal Bilirubin Encephalopathy. Clinical
characteristics of bilirubin encephalopathy in Chinese newborn
infants-a national multicenter survey. Zhonghua Er Ke Za Zhi
2012;50:331e5 [Article in Chinese].
24. Huang MJ, Kua KE, Teng HC, Tang KS, Weng HW, Huang CS. Risk
factors for severe hyperbilirubinemia in neonates. Pediatr Res
2004;56:682e9.
25. Zhou Y, Wang SN, Li H, Zha W, Wang X, Liu Y, et al. Association
of UGT1A1 Variants and Hyperbilirubinemia in Breast-Fed Full-
Term Chinese Infants. PLoS ONE 2014;9:e104251.
26. Watchko JF, Lin Z. Exploring the genetic architecture of
neonatal hyperbilirubinemia. Semin Fetal Neonatal Med 2010;
15:169e75.
27. Sato H, Uchida T, Toyota K, Kanno M, Hashimoto T,
Watanabe M, et al. Association of breast-fed neonatal hyper-
bilirubinemia with UGT1A1 polymorphisms: 211G>A (G71R)
mutation becomes a risk factor under inadequate feeding. J
Hum Genet 2013;58:7e10.
28. Long J, Zhang S, Fang X, Luo Y, Liu J. Association of neonatal
hyperbilirubinemia with uridine diphosphate-
glucuronosyltransferase 1A1 gene polymorphisms: Meta-anal-
ysis. Pediatr Int 2011;53:530e40.
29. Huang CS, Luo GA, Huang ML, Yu SC, Yang SS. Variations of the
bilirubin uridine-diphosphoglucuronosyl transferase 1A1 gene
in healthy Taiwanese. Pharmacogenetics 2000;10:539e44.
30. Yamamoto K, Sato H, Fujiyama Y, Doida Y, Bamba T. Contri-
bution of two missense mutations (G71R and Y486D) of the
bilirubin UDP glycosyltransferase (UGT1A1) gene to phenotypes
of Gilbert’s syndrome and Crigler-Najjar syndrome type II.
Biochim Biophys Acta 1998;1406:267e73.
31. Di YM, Chan E, Wei MQ, Liu JP, Zhou SF. Prediction of delete-
rious non-synonymous single-nucleotide polymorphisms of
human uridine diphosphate glucuronosyltransferase genes.
AAPS J 2009;11:469e80.
32. Glucose-6-phosphate dehydrogenase deficiency. WHO Working
Group. Bull World Health Organ 1989;67:601e11.
33. Riskin A, Gery N, Kugelman A, Hemo M, Spevak I, Bader D.
Glucose-6-phosphate dehydrogenase deficiency and borderline
Genetic basis of severe neonate jaundice 317deficiency: association with neonatal hyperbilirubinemia. J
Pediatr 2012;161:191e6.
34. Kaplan M, Hammerman C. Glucose-6-phosphate dehydrogenase
deficiency and severe neonatal hyperbilirubinemia: a
complexity of interactions between genes and environment.
Semin Fetal Neonatal Med 2010;15:148e56.
35. Herschel M, Ryan M, Gelbart T, Kaplan M. Hemolysis and
hyperbilirubinemia in an African American neonate heterozy-
gous for glucose-6-phosphate dehydrogenase deficiency. J
Perinatol 2002;22:577e9.
36. Weatherall DJ. Hemoglobinopathies worldwide: present and
future. Curr Mol Med 2008;8:592e9.37. Chou HC, Chen MH, Yang HI, Su YN, Hsieh WS, Chen CY, et al.
211 G to a variation of UDP-glucuronosyl transferase 1A1 gene
and neonatal breastfeeding jaundice. Pediatr Res 2011;69:
170e4.
38. Ota Y, Maruo Y, Matsui K, Mimura Y, Sato H, Takeuchi Y.
Inhibitory effect of 5b-pregnane-3a,20b-diol on transcriptional
activity and enzyme activity of human bilirubin UDP-glucur-
onosyltransferase. Pediatr Res 2011;70:453e7.
39. Fujiwara R, Chen S, Karin M, Tukey RH. Reduced expression of
UGT1A1 in intestines of humanized UGT1 mice via inactivation
of NF-kB leads to hyperbilirubinemia. Gastroenterology 2012;
142:109e18.
